The winner turned out to be the paper «Targeting SAMHD1 with the Vpx protein to
improve cytarabine therapy for hematological malignancies» (DOI: 10.1038 / nm.4265), presented by Sean Rudd.
Not exact matches
1) Rituximab was added to the induction as the majority of PCNSL are CD20 + diffuse large B - cell lymphomas (DLBCL) and it was previously shown that the addition of rituximab to CHOP chemotherapy has
improved the prognosis in DLBCL outside the brain.8 2) The intraventricular MTX /
cytarabine treatment of the Bonn protocol requiring an Ommaya reservoir was replaced by intraspinal administration of liposomal
cytarabine in view of the expected lower risk of procedure - related infections.
High - Dose Chemotherapy Plus Transplant Not Recommended for DLBCL: The results of an Italian study report that treatment of high - risk diffuse large B - cell lymphoma (DLBCL) with abbreviated course of rituximab dose - dense chemotherapy plus high - dose
cytarabine, mitoxantrone, and dexamethasone (R - MAD) plus carmustine, etoposide,
cytarabine, and melphalan (BEAM) plus autologous stem cell transplantation compared with a full course of rituximab dose - dense chemotherapy did not
improve overall survival.